Department of Pediatrics, University of Kentucky College of Medicine, Lexington, Kentucky, United States of America.
Graduate Center for Toxicology, University of Kentucky College of Medicine, Lexington, Kentucky, United States of America.
PLoS One. 2014 Jan 15;9(1):e85702. doi: 10.1371/journal.pone.0085702. eCollection 2014.
Thiamine-dependent enzymes (TDEs) control metabolic pathways that are frequently altered in cancer and therefore present cancer-relevant targets. We have previously shown that the recombinant enzyme thiaminase cleaves and depletes intracellular thiamine, has growth inhibitory activity against leukemia and breast cancer cell lines, and that its growth inhibitory effects were reversed in leukemia cell lines by rapamycin. Now, we first show further evidence of thiaminase therapeutic potential by demonstrating its activity against breast and leukemia xenografts, and against a primary leukemia xenograft. We therefore further explored the metabolic effects of thiaminase in combination with rapamycin in leukemia and breast cell lines. Thiaminase decreased oxygen consumption rate and increased extracellular acidification rate, consistent with the inhibitory effect of acute thiamine depletion on the activity of the TDEs pyruvate dehydrogenase and 2-oxoglutarate dehydrogenase complexes; these effects were reversed by rapamycin. Metabolomic studies demonstrated intracellular thiamine depletion and the presence of the thiazole cleavage product in thiaminase-treated cells, providing validation of the experimental procedures. Accumulation of ribose and ribulose in both cell lines support the thiaminase-mediated suppression of the TDE transketolase. Interestingly, thiaminase suppression of another TDE, branched chain amino ketoacid dehydrogenase (BCKDH), showed very different patterns in the two cell lines: in RS4 leukemia cells it led to an increase in BCKDH substrates, and in MCF-7 breast cancer cells it led to a decrease in BCKDH products. Immunoblot analyses showed corresponding differences in expression of BCKDH pathway enzymes, and partial protection of thiaminase growth inhibition by gabapentin indicated that BCKDH inhibition may be a mechanism of thiaminase-mediated toxicity. Surprisingly, most of thiaminase-mediated metabolomic effects were also reversed by rapamycin. Thus, these studies demonstrate that acute intracellular thiamine depletion by recombinant thiaminase results in metabolic changes in thiamine-dependent metabolism, and demonstrate a previously unrecognized role of mTOR signaling in the regulation of thiamine-dependent metabolism.
依赖硫胺素的酶(TDE)控制代谢途径,这些途径在癌症中经常发生改变,因此是与癌症相关的靶点。我们之前已经表明,重组酶硫胺酶可切割并耗尽细胞内硫胺素,对白血病和乳腺癌细胞系具有生长抑制活性,并且其生长抑制作用可被雷帕霉素逆转。现在,我们通过证明其对乳腺癌和白血病异种移植物以及原发性白血病异种移植物的活性,首次提供了硫胺酶治疗潜力的进一步证据。因此,我们进一步探索了硫胺酶与雷帕霉素联合在白血病和乳腺癌细胞系中的代谢作用。硫胺酶降低耗氧率并增加细胞外酸化率,这与急性硫胺素耗竭对 TDE 丙酮酸脱氢酶和 2-氧戊二酸脱氢酶复合物活性的抑制作用一致;这些作用可被雷帕霉素逆转。代谢组学研究表明,硫胺酶处理的细胞中存在细胞内硫胺素耗竭和噻唑裂解产物,为实验程序提供了验证。两种细胞系中核糖和核酮糖的积累均支持硫胺酶介导的 TDE 转酮醇酶抑制作用。有趣的是,硫胺酶对另一种 TDE 支链氨基酸酮酸脱氢酶(BCKDH)的抑制在两种细胞系中表现出非常不同的模式:在 RS4 白血病细胞中,它导致 BCKDH 底物增加,而在 MCF-7 乳腺癌细胞中,它导致 BCKDH 产物减少。免疫印迹分析显示 BCKDH 途径酶的表达存在相应差异,加巴喷丁对硫胺酶生长抑制的部分保护表明 BCKDH 抑制可能是硫胺酶介导毒性的一种机制。令人惊讶的是,大多数由硫胺酶介导的代谢组学效应也可被雷帕霉素逆转。因此,这些研究表明,重组硫胺酶引起的急性细胞内硫胺素耗竭导致硫胺素依赖性代谢的代谢变化,并表明 mTOR 信号在调节硫胺素依赖性代谢中的作用以前未被认识到。